CN1412183A - New preparation method of timixatan - Google Patents
New preparation method of timixatan Download PDFInfo
- Publication number
- CN1412183A CN1412183A CN 01131915 CN01131915A CN1412183A CN 1412183 A CN1412183 A CN 1412183A CN 01131915 CN01131915 CN 01131915 CN 01131915 A CN01131915 A CN 01131915A CN 1412183 A CN1412183 A CN 1412183A
- Authority
- CN
- China
- Prior art keywords
- synthetic method
- telmisartan
- water
- solvent
- hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The prsent invention relates to a preparation method of timisatan as active component of medicine for resisting hypertension. It is characterized by that after the intermediate I and 4'-bromomethylbiphenyl-2-nitrile are undergone the nucleophilic substitution reaction to obtain nitrile derivative of timisatan, the nitrile group of said nitrile derivative is hydrolyzed into carboxyl to obtain the end product timisatan with high purity.
Description
Technical field
The present invention relates to a kind of preparation method of new antihypertensive drug telmisartan (Telmisartan).
Background technology
Telmisartan is a kind of novel non-peptide class Angiotensin II (ATII) receptor antagonist.Its structure is as follows:
The synthetic route (Scheme 1) of existing telmisartan mainly is, and to be starting raw material with 3-methyl-4-Methyl anthranilate get intermediate 2-n-propyl-4-methyl-6-(1-tolimidazole-2-yl) benzoglyoxaline (I) through N-acidylate, nitrated, reduction, cyclization, ester hydrolysis, condensation reaction; I and 4 '-bromomethylbiphenyl-2-carboxylic acid tert-butyl ester nucleo philic substitution reaction obtains Compound I I; II is hydrolyzed to final product telmisartan (III) (Ries U again; Mihm G; Narr B etc.; J Med Chem; 1993,36:4040-4051).Through improving, also can adopt 4 '-bromomethylbiphenyl-2-carboxylate methyl ester or 4 '-be hydrolyzed to telmisartan (Shen Jingshan, Li Jianfeng, tight iron-clad horses etc. again after bromomethylbiphenyl-2-carboxylic acid, ethyl ester and the I reaction, the new synthesis process .Appl.No.:CN 01126367.9,2001 of telmisartan).In existing preparation method, all be earlier with ester group protection 4 '-carboxyl of bromomethylbiphenyl-2-carboxylic acid, again with the I reaction, but 4 '-bromomethylbiphenyl-2-carboxylicesters needs preparation separately, thereby make total synthesis step more, production cost is also higher.
Scheme?1
Summary of the invention
The present invention seeks to seek the more easy industrial production process of telmisartan.
The present invention implements by following reaction.
The present invention adopts 4 '-bromomethylbiphenyl-2-nitrile replaces 4 '-bromomethylbiphenyl-2-carboxylicesters carries out nucleophilic substitution reaction generation IV with I, and the cyan-hydrolysis with IV is that carboxyl gets object III again.Route is shown in Scheme 2.
Scheme2
The present invention includes the following step:
(1) 2-n-propyl-4-methyl-6-(1-tolimidazole-2-yl) benzoglyoxaline (I) and 4 '-bromomethylbiphenyl-2-nitrile nucleo philic substitution reaction generates 4 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-nitrile (IV).More particularly, be to adopt organic bases (for example sodium alkoxide, triethylamine, tri-n-butylamine, tripropylamine) or mineral alkali (for example NaOH, KOH, CsOH, Ba (OH)
2, Mg (OH)
2, Ca (OH)
2, Sr (OH)
2, KHCO
3, K
2CO
3, Na
2CO
3, Cs
2CO
3) be the disacidify agent, 20～80 ℃ temperature range internal reactions 4～6 hours, generate intermediate compound IV.Reaction solvent can be selected DMF, DMSO, THF, dioxane, pyrrolidinone compounds, hexamethylphosphoramide, acetone, glycol dimethyl ether, CH for use
2Cl
2, ethylene dichloride etc.
(2) cyan-hydrolysis of IV be sour 4 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-carboxylic acid (III), i.e. telmisartan.IV can be at acidic conditions (H for example
2SO
4, concentrated hydrochloric acid, Hydrogen bromide, concentrated hydrochloric acid/Glacial acetic acid, Hydrogen bromide/Glacial acetic acid etc.) hydrolysis down, temperature of reaction can be controlled in room temperature to the scope of reflux state.IV also can be under alkaline condition, more particularly, is at mineral alkali (for example NaOH, KOH, CsOH, Ba (OH)
2, Mg (OH)
2, Ca (OH)
2, Sr (OH)
2, KHCO
3, K
2CO
3, Na
2CO
3, Cs
2CO
3) or organic bases (for example sodium alkoxide) existence is down, with C
1～C
5Lower alcohol (for example methyl alcohol, ethanol, Virahol, propyl carbinol, isopropylcarbinol, the trimethyl carbinol, Pentyl alcohol, primary isoamyl alcohol, ethylene glycol, propylene glycol) and water (alcohol: water=1～9: 9～1, V: mixed solvent V) or other solvent (for example DMF, DMSO, THF, dioxane, pyrrolidinone compounds) and water (other solvent: water=1～9: 9～1, V: mixed solvent V) is a solvent, 30～160 ℃ temperature range internal reactions 10～20 hours, be hydrolyzed to object III.
The present invention has following advantage:
1. 4 '-bromomethylbiphenyl-2-nitrile than 4 '-bromomethylbiphenyl-2-carboxylicesters especially 4 '-bromomethylbiphenyl-2-carboxylic acid tert-butyl ester is more stable, and existing market raw material supply, cheap, do not need to prepare separately, thereby make total reactions steps be less than existing bibliographical information route, also reduced cost.
2. 4 '-speed of response of bromomethylbiphenyl-2-nitrile and I is fast, the reaction conditions gentleness, and gained intermediate compound IV good stability, the purity height is guaranteed the quality of the finished product III and yield.
3. easily-controlled reaction conditions is easy and simple to handle, is suitable for scale operation.
Embodiment
Below each embodiment further specify the present invention, but do not impose any restrictions.
Embodiment 14 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-nitrile (IV)
With I (30.4g, 0.10mol), 4 '-bromomethylbiphenyl-2-nitrile (29.9g, 0.11mol), K
2CO
3(41.4g 0.3mol) (300ml) mixes with DMF (or other solvent) as previously mentioned fine powder (or other mineral alkali) as previously mentioned, about 5 hours of 40 ℃ of reactions.TLC is poured into reaction solution in the frozen water (600g) after detecting no raw material, with ethyl acetate extraction (300ml * 3), merges organic phase, water Shen (300ml * 2), saturated common salt washing (300ml).Be evaporated to small volume behind the anhydrous sodium sulfate drying, drip sherwood oil to solid under stirring and separate out.Get IV crude product (45.5g, 91.9%).Can not purifiedly be directly used in the next step.Analytic sample gets white solid with ethyl acetate-sherwood oil recrystallization.
1HNMR(CDCl
3)：1.05(3H，t，CH
2CH
3)，1.88(2H，m，CH
2CH
2CH
3)，2.79(3H，s，Ar-CH
3)，2.92(2H，t，CH
2CH
2CH
3)，3.86(3H，s，NCH
3)，5.44(2H，s，ArCH
2)，7.17～7.82(14H，m，ArH)。MS (EI) m/z:495 (M
+, base peak), 480,467,452,303,274,192,165.
Embodiment 24 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-nitrile (IV)
With I (30.4g, 0.10mol), 4 '-bromomethylbiphenyl-2-nitrile (29.9g, 0.11mol), (20.4g 0.3mol) (300ml) mixes with dry DMF (or other solvent) as previously mentioned sodium ethylate (or other organic bases) as previously mentioned, 80 ℃ of reactions 3 hours.Aftertreatment is with embodiment 1.
Embodiment 34 '-[(1,4 '-dimethyl 2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-carboxylic acid (III)
(24.8g 0.05mol) mixes with glacial acetic acid (150ml) and concentrated hydrochloric acid (300ml) (or other acid as previously mentioned), and 100 ℃ were reacted 10 hours to get step gained IV.Concentrating under reduced pressure removes most of nitration mixture, and excess slowly is poured in the water (500g), stirs, and promptly has solid to separate out, and filters, and a small amount of washing gets the III crude product, gets III (22.2g, 86.4%, HPLC＞99.0%) with the DMF recrystallization.mp?261～263℃。
1HNMR(DMSO-d
6)：0.98(3H，t，CH
2CH
3)，1.80(2H，m，CH
2CH
2CH
3)，2.61(3H，s，Ar-CH
3)，2.92(2H，t，CH
2CH
2CH
3)，3.81(3H，s，NCH
3)，5.62(2H，s，ArCH
2)，7.15～7.73(14H，m，ArH)。MS (EI) m/z:515 (M+1), 469 (base peaks), 442,303,274,165,77.
Embodiment 44 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-carboxylic acid (III)
(24.8g 0.05mol) adds ethanol (or other solvent) as previously mentioned (200ml) to IV, NaOH (8.0g, 0.2mol) (or other alkali) as previously mentioned, water (100ml), back flow reaction 10 hours.Decompression recycling ethanol is to the long-pending 60ml that is about of remaining liquid, dripping hydrochloric acid (1: 1) to pH be 5～6, have solid to separate out, filter, washing, the III crude product, get III (20.4g, 79.5%) with the DMF recrystallization.
Embodiment 54 '-[(1,4 '-dimethyl 2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-2-carboxylic acid (III)
IV (24.8g, 0.05mol) add ethylene glycol (100ml) and water (150ml) (or other mixed solvent) as previously mentioned, sodium ethylate (or other sodium alkoxide) as previously mentioned (13.6g, 0.2mol), back flow reaction 10 hours.TLC is chilled to room temperature after detecting no raw material, dripping hydrochloric acid (1: 1) to pH be 5～6, have solid to separate out, filter, washing must III.
Claims (10)
1. telmisartan synthetic method that reactions steps is following:
Via starting raw material 2-n-propyl-4-methyl-6-(1-tolimidazole-2-yl) benzoglyoxaline and 4 '-bromomethylbiphenyl-2-nitrile is in the presence of organic bases or mineral alkali, in reaction solvent, under the certain temperature, the nucleophilic substitution reaction that carries out a few hours makes key intermediate 4 '-[(1,4 '-dimethyl-2 '-propyl group [2,6 '-two-1H-benzoglyoxaline]-1 '-yl) methyl]-[1,1 '-biphenyl]-the 2-nitrile, be hydrolyzed to telmisartan then.
2. it is characterized in that according to the described telmisartan synthetic method of claim 1 nucleophilic substitution reaction is the disacidify agent with the organic bases, organic bases is sodium alkoxide, triethylamine, tri-n-butylamine, tripropylamine.
3. it is characterized in that the agent of mineral alkali disacidify according to the described telmisartan synthetic method of claim 1, mineral alkali is NaOH, KOH, CsOH, Ba (OH)
2, Mg (OH)
2, Ca (OH)
2, Sr (OH)
2, KHCO
3, K
2CO
3, Na
2CO
3, Cs
2CO
3
4. it is characterized in that according to the described telmisartan synthetic method of claim 1 the nucleophilic substitution reaction temperature is 20～80 ℃, the reaction times is 4～6 hours.
5. it is characterized in that according to the described telmisartan synthetic method of claim 1 the nucleophilic substitution reaction solvent is DMF, DMSO, THF, dioxane, pyrrolidinone compounds, hexamethylphosphoramide, acetone, glycol dimethyl ether, CH
2Cl
2, ethylene dichloride.
6. it is characterized in that according to the described telmisartan synthetic method of claim 1 cyan-hydrolysis carries out under acidic conditions, available H
2SO
4, concentrated hydrochloric acid, Hydrogen bromide, concentrated hydrochloric acid/Glacial acetic acid, Hydrogen bromide/Glacial acetic acid hydrolysis, hydrolysis temperature is that room temperature is between the reflux state.
7. it is characterized in that according to the described telmisartan synthetic method of claim 1 cyan-hydrolysis carries out under alkaline condition, with C
1～C
5The mixed solvent of the mixed solvent of lower alcohol and water or other solvents and water was a solvent, 30～160 ℃ of reactions 10～20 hours.
8. it is characterized in that according to the described telmisartan synthetic method of claim 7 mineral alkali is NaOH, KOH, CsOH, Ba (OH)
2, Mg (OH)
2, Ca (OH)
2, Sr (OH)
2, KHCO
3, K
2CO
3, Na
2CO
3, Cs
2CO
3
9. it is characterized in that according to the described telmisartan synthetic method of claim 7 organic bases is a sodium alkoxide.
1O. it is characterized in that according to the described telmisartan synthetic method of claim 7 solvent of hydrolysis reaction is C
1～C
5The mixed solvent of lower alcohol and water, its ratio are alcohol: water=1～9: 9～1 (V: V), or the mixed solvent of other solvents such as DMF, DMSO, THF, dioxane, pyrrolidinone compounds and water, its ratio is other solvents: water=1～9: 9～1 (V: V).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131915 CN1204124C (en) | 2001-10-15 | 2001-10-15 | New preparation method of timixatan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01131915 CN1204124C (en) | 2001-10-15 | 2001-10-15 | New preparation method of timixatan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1412183A true CN1412183A (en) | 2003-04-23 |
| CN1204124C CN1204124C (en) | 2005-06-01 |
Family
ID=4670970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01131915 Expired - Fee Related CN1204124C (en) | 2001-10-15 | 2001-10-15 | New preparation method of timixatan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1204124C (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044648A1 (en) * | 2004-10-15 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing telmisartan |
| CN101172968B (en) * | 2006-11-01 | 2010-05-12 | 浙江天宇药业有限公司 | 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same |
| WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
| CN101550107B (en) * | 2009-04-02 | 2011-01-12 | 宁波九胜创新医药科技有限公司 | Method for preparing telmisartan |
| EP2277866A1 (en) | 2009-06-22 | 2011-01-26 | Inke, S.A. | Process for preparing telmisartan |
| WO2012028925A2 (en) | 2010-09-03 | 2012-03-08 | Ogene Systems (I) Pvt Ltd | An improved process for the preparation of telmisartan |
| CN101743228B (en) * | 2007-07-03 | 2014-01-29 | 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 | Process for preparing telmisartan |
| US8691999B2 (en) | 2004-05-11 | 2014-04-08 | Cipla Limited | Process for the preparation of telmisartan |
| CN105399627A (en) * | 2015-10-22 | 2016-03-16 | 威特(湖南)药业有限公司 | Synthetic method of 4'-bromomethylbiphenyl-2-carboxylate |
| CN109912512A (en) * | 2017-12-13 | 2019-06-21 | 上海科胜药物研发有限公司 | A kind of new Telmisartan impurity compound and its preparation method and application |
-
2001
- 2001-10-15 CN CN 01131915 patent/CN1204124C/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691999B2 (en) | 2004-05-11 | 2014-04-08 | Cipla Limited | Process for the preparation of telmisartan |
| WO2006044648A1 (en) * | 2004-10-15 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing telmisartan |
| US7501448B2 (en) | 2004-10-15 | 2009-03-10 | Teva Pharmaceutical Industries, Ltd. | Process for preparing telmisartan |
| CN101172968B (en) * | 2006-11-01 | 2010-05-12 | 浙江天宇药业有限公司 | 2-propyl-4 methyl-6-(tolimidazole-2group) benzoglioxaline salt and method for producing the same |
| CN101743228B (en) * | 2007-07-03 | 2014-01-29 | 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 | Process for preparing telmisartan |
| CN101550107B (en) * | 2009-04-02 | 2011-01-12 | 宁波九胜创新医药科技有限公司 | Method for preparing telmisartan |
| WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
| EP2277866A1 (en) | 2009-06-22 | 2011-01-26 | Inke, S.A. | Process for preparing telmisartan |
| WO2012028925A2 (en) | 2010-09-03 | 2012-03-08 | Ogene Systems (I) Pvt Ltd | An improved process for the preparation of telmisartan |
| CN105399627A (en) * | 2015-10-22 | 2016-03-16 | 威特(湖南)药业有限公司 | Synthetic method of 4'-bromomethylbiphenyl-2-carboxylate |
| CN109912512A (en) * | 2017-12-13 | 2019-06-21 | 上海科胜药物研发有限公司 | A kind of new Telmisartan impurity compound and its preparation method and application |
| CN109912512B (en) * | 2017-12-13 | 2023-05-30 | 上海科胜药物研发有限公司 | New telmisartan impurity compound and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1204124C (en) | 2005-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102766138B (en) | A kind of preparation method of Azilsartan | |
| CN1182122C (en) | Synthesis path of Timisatem | |
| CN1204124C (en) | New preparation method of timixatan | |
| CN101024631A (en) | Intermediate of telmisartan, its preparation and use | |
| CN102395591B (en) | Method for preparing prasugrel | |
| CN102086169B (en) | Preparation method of intermediates of Febuxostat | |
| CN102911128A (en) | Synthetic method of valsartan | |
| CN102267949A (en) | New process for telmisartan preparation | |
| CN109456329A (en) | A kind of preparation method of famciclovir | |
| CN117756801A (en) | Preparation method of non-neridrone | |
| CN102267934B (en) | Method for preparing 6-carbomethoxy indolone | |
| CN106748966A (en) | A kind of synthetic method of Ramipril key intermediate | |
| CN102070533A (en) | New method for synthesizing 4-(1-hydroxyl-1-methyl ethyl)-2-propyl imidazole-5-carboxylic acid ethyl ester | |
| CN101921235A (en) | Preparation method of telmisartan | |
| CN101863954A (en) | Preparation method of N-tert-butyl-4-aza-5 alpha-androstane-3-ketone-17 beta-formamide | |
| CN101391982B (en) | Alkylation reaction method of benzimidazoles compounds | |
| CN104151283B (en) | One catalyzes and synthesizes the method for 12-aryl-8,9,10,12-tetrahydro benzo [α] xanthene-11-ketone derivatives | |
| CN101607950A (en) | The method for preparing the amino benzofurancarboxylic acid ester of 5- | |
| CN101838243A (en) | Method for refining telmisartan | |
| CN106349214B (en) | Preparation method of bilastine impurity | |
| CN106748725B (en) | preparation method of 4-chloro-2-fluoro-phenylpropionic acid | |
| CN101260079B (en) | Method for preparing 7,8-dihydroquinolin-2,5(1H,6H)-diones derivatives | |
| CN104370865A (en) | Method for synthesizing 3-(2,3-dihydrobenzofuran-5-yl) propionic acid through Heck reaction | |
| CN103709089B (en) | One prepares the method for 3-(4 '-chlorobutyl)-5-cyanoindole | |
| CN104098556A (en) | Novel synthetic process for rivaroxaban |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 294 Taiyuan Road, Shanghai, zip code: 200031 Co-patentee after: TOPHARMAN SHANGHAI Co.,Ltd. Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Address before: 294 Taiyuan Road, Shanghai, zip code: 200031 Co-patentee before: Shanghai Tehua Pharmaceutical and Chemical Co.,Ltd. Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20081212 Address after: The German Ingelheim 55216 accusative Street No. 173 Patentee after: BOEHRINGER INGELHEIM INTERNATIONAL GmbH Address before: 294 Taiyuan Road, Shanghai, zip code: 200031 Co-patentee before: TOPHARMAN SHANGHAI Co.,Ltd. Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
| ASS | Succession or assignment of patent right |
Owner name: BOEHRINGER INGELHEIM INTERNATIONAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI PHARMACEUTICAL INST., CHINESE ACADEMY OF SCIENCES Effective date: 20081212 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050601 Termination date: 20131015 |